FERDINAND Study: Weight Loss for Diabetes Prevention
Would you like to participate in a 6-month weight loss and weight loss maintenance nutrition study to reduce diabetes risk?
Study title: Evaluating feijoa for diabetes prevention in a multi-ethnic New Zealand cohort
We are investigating whether daily consumption of feijoa whole fruit powder alters risk of developing type 2 diabetes through weight loss.
You will be required to:
- Attend 7 study visits at the Human Nutrition Unit, in Mt Eden
- Follow the low energy, Cambridge weight-loss diet for 8 weeks
- Complete a 4-month weight maintenance programme
- Consume feijoa whole fruit powder or placebo matched powder every day for 6 months
What's in it for you?
- 2 months’ worth of meal replacements at no cost
- 9 extensive dietary advice sessions with a Registered Dietitian
- Free body composition scans to understand your body fat mass, lean mass, and bone mineral density
- Try a continuous glucose monitor (CGM) to know what meals raise your blood glucose more than others
- Get to know how many calories your body burns when at rest using an indirect calorimetry
- Your time will be compensated with travel vouchers
- Have elevated blood glucose but are not diabetic (we can check this for you)
- Are of Māori, Pacific Island, Asian Indian, Asian Chinese or NZ European/Caucasian descent
- Are between 18-70 years
- Have a BMI 26-40kg/m2
- Are happy to participate in a 6-month weight loss study
- Are happy to consume feijoa whole fruit powder or matched placebo powder every day for 8 months
- Are happy for us to provide blood, urine and faecal samples
- Are happy to complete 7 visits to the Human Nutrition Unit
IMPORTANT: You cannot participate in the study if you have already been diagnosed with type 2 diabetes.
Complete the pre-screening survey here.
If you have any further questions please visit our FAQ page.
If you would like to learn more about this study, please contact us:
Phone: 09 630 1162
Statement of ethics approval
Approved by the Southern Health and Disability Ethics Committee on 16 March 2022.
Reference number: 2022 EXP 12032